My article published on the site disabiliabili.net
heavy metals cause serious illnesses . Toxic metals play an important role in the onset of neurodegenerative diseases (ND). By studying the molecular basis for this heterogeneous group of diseases, there was evidence that these metals are involved in the onset and progression of diseases that affect the conformation of specific proteins that cause oxidative stress or local. The apparently critical role played by dissociation for homeostasis of metals in ND makes chelation therapy a pharmacologically interesting option.
However, the classical method of chelation with strong chelating agents, was successful only in those rare cases where the high concentration of metal in the brain is linked to specific defects in the metabolism of metal. Methods of chelating ligands with medium intensity, seem to be the best suited to combat ND, even if their benefits have yet been put into doubt. The prospects for the development of new agents effective against ND are critically discussed.
chronic poisoning Heavy metals and chelation therapy 'effective? studies have shown that chelation therapy is effective only in acute poisoning and in those that are the cause of many chronic neurodegenerative diseases is not. In fact, the 'CaNa2EDTA chelating agent can not pass through cell membranes and therefore its use is limited to the removal of metal ions from their complexes in the extracellular fluid. In the same way, although considered safer than DMSA, shares the limitation of the extracellular distribution. This fact makes the DMSA ineffective in cases of metal poisoning (especially lead and arsenic) that occur in small doses, slowly, in a chronic, because the metals reach the cellular compartments beyond the physiological barriers including the blood-brain barrier. Although the treatment with DMSA and DMPS showed minor adverse effects, the loss of essential metals, particularly copper and zinc, can be considered as one of the most important limitations.
There are risks in chelation therapy? ancora.Ci There are controversial studies are studies that say that the doses of chelation therapy, like EDTA, are very low compared to the past and therefore there is no risk. There are however studies that confirm that the risks are associated with the risk of depletion of essential trace elements in chelation therapy Classic. With CaNa2EDTA therapy are substantial, including renal failure, arrhythmias, tetany, hypocalcemia, hypotension, bone marrow suppression, delay in blood clotting, seizures, respiratory arrest, etc.. Although the nephrotoxicity of CaNa2EDTA decreases after cessation of therapy, exceeding the maximum daily dose of 75 mg / kg can be fatal. Other side effects may include fatigue, headache, fever, nasal congestion, watery eyes, mucocutaneous lesions, glycosuria, myalgia, complications in the metabolic processes of the liver, increased urinary frequency, and ECG abnormalities in gastrointestinal symptoms. Prolonged treatment with CaNa2EDTA results in lack of some essential metals, especially Zn, Cu and Mn. It was reported that zinc supplementation during and after chelation may be of benefit. The removal of zinc can be seen as an event of teratogenicity of CaNa2EDTA.
The test for 'heavy metal poisoning . The HTMA (it's a laboratory that can perform on a small amount of skin appendages (hair, pubic hair, nails). This method is considered equivalent to a biopsy (biopsy = removal of a body tissue) and is for determining levels of intracellular minerals. All information http://mineraltest.wordpress.com/2010/04/07/analisi-minerale-tissutale/
Source: http://mineraltest.wordpress.com/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922724/?tool=pubmed
(http : / / www.interscience.wiley.com). doi /
http://guide.supereva.it/
heavy metals cause serious illnesses . Toxic metals play an important role in the onset of neurodegenerative diseases (ND). By studying the molecular basis for this heterogeneous group of diseases, there was evidence that these metals are involved in the onset and progression of diseases that affect the conformation of specific proteins that cause oxidative stress or local. The apparently critical role played by dissociation for homeostasis of metals in ND makes chelation therapy a pharmacologically interesting option.
However, the classical method of chelation with strong chelating agents, was successful only in those rare cases where the high concentration of metal in the brain is linked to specific defects in the metabolism of metal. Methods of chelating ligands with medium intensity, seem to be the best suited to combat ND, even if their benefits have yet been put into doubt. The prospects for the development of new agents effective against ND are critically discussed.
What ' chelation therapy. Chelation therapy is the preferred treatment for reducing the toxic effects of metals. Chelating agents are able to bind to toxic metal ions to form complex structures that are removed by intracellular and extracellular spaces becoming so easily eliminated from the body. The 2.3-dimercaptopropanolo (BAL) has long been the mainstay of chelation therapy in cases of lead and arsenic poisoning, but his serious side effects have led researchers to develop less toxic analogues. The hydrophilic binders such as acid meso-2 ,3-dimercaptosuccinic acid (DMSA) effectively promote renal excretion of the metal, but their ability to access intracellular metal is weak. Newer strategies to address these problems are the combination therapy (use of structurally different chelating agents) or co-administration of antioxidants.
There are risks in chelation therapy? ancora.Ci There are controversial studies are studies that say that the doses of chelation therapy, like EDTA, are very low compared to the past and therefore there is no risk. There are however studies that confirm that the risks are associated with the risk of depletion of essential trace elements in chelation therapy Classic. With CaNa2EDTA therapy are substantial, including renal failure, arrhythmias, tetany, hypocalcemia, hypotension, bone marrow suppression, delay in blood clotting, seizures, respiratory arrest, etc.. Although the nephrotoxicity of CaNa2EDTA decreases after cessation of therapy, exceeding the maximum daily dose of 75 mg / kg can be fatal. Other side effects may include fatigue, headache, fever, nasal congestion, watery eyes, mucocutaneous lesions, glycosuria, myalgia, complications in the metabolic processes of the liver, increased urinary frequency, and ECG abnormalities in gastrointestinal symptoms. Prolonged treatment with CaNa2EDTA results in lack of some essential metals, especially Zn, Cu and Mn. It was reported that zinc supplementation during and after chelation may be of benefit. The removal of zinc can be seen as an event of teratogenicity of CaNa2EDTA.
The test for 'heavy metal poisoning . The HTMA (it's a laboratory that can perform on a small amount of skin appendages (hair, pubic hair, nails). This method is considered equivalent to a biopsy (biopsy = removal of a body tissue) and is for determining levels of intracellular minerals. All information http://mineraltest.wordpress.com/2010/04/07/analisi-minerale-tissutale/
Source: http://mineraltest.wordpress.com/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922724/?tool=pubmed
(http : / / www.interscience.wiley.com). doi /
http://guide.supereva.it/
0 comments:
Post a Comment